Related Experiment Videos
Gaucher's disease: a paradigm for interventional genetics.
1Clinical Genetics Unit, Hôpital Européen Georges Pompidou, Paris, France. dominique.germain@hop.egp.ap-hop-paris.fr
Clinical Genetics
|February 27, 2004
Summary
Gaucher's disease (GD) is a genetic disorder affecting glycosphingolipid metabolism. Enzyme replacement therapy (ERT) effectively treats type 1 GD, but neurological symptoms in types 2 and 3 remain challenging.
Area of Science:
- Biochemistry
- Genetics
- Rare Diseases
Background:
- Gaucher's disease (GD) is a prevalent lysosomal storage disorder (LSD) caused by acid beta-glucosidase deficiency.
- It's an autosomal recessive metabolic disorder affecting glycosphingolipid breakdown.
- GD presents in three types, with type 1 affecting organs and types 2 and 3 involving neurological symptoms.
Purpose of the Study:
- To review the current understanding of Gaucher's disease.
- To discuss the available and emerging therapeutic strategies.
- To highlight areas of ongoing research, including genotype/phenotype correlations.
Main Methods:
- Literature review of Gaucher's disease pathogenesis and treatment.
- Analysis of enzyme replacement therapy (ERT) efficacy.
- Overview of novel therapeutic approaches.
Main Results:
- Enzyme replacement therapy (ERT) with imiglucerase is the standard of care for type 1 GD, showing efficacy in organomegaly and hematological parameters.
- ERT improves bone disease but does not reverse neurological deficits in types 2 and 3 GD.
- Substrate reduction therapy and gene therapy are promising future treatments.
Conclusions:
- ERT is effective for type 1 Gaucher's disease, with ongoing research into managing other types.
- Understanding genotype/phenotype relationships is crucial for personalized treatment.
- Novel therapies are being developed to address unmet needs in GD management.